On January 13th, research teams from Shanghai University of Traditional Chinese Medicine, National Key Laboratory of Lead Druggability Research, Naval Medical University, and Chinese Academy of Medical Sciences & Peking Union Medical College published a groundbreaking research paper titled "Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer" in the journal "Cell Reports Medicine" (impact factor: 11.7).
This research highlights the critical role of tumor-associated neutrophils (TANs) in the progression and prognosis of triple-negative breast cancer (TNBC), focusing on the pro-tumor characteristics of N2-type TANs. The study introduces CT-1, a cryptotanshinone derivative, which effectively suppresses TNBC growth while selectively reducing N2-type TANs within tumor tissue. CT-1 induces ferroptosis in both N2-type TANs and TNBC cells, enhancing therapeutic efficacy. Ferritin heavy chain 1 (FTH1) is identified as the direct target of CT-1, facilitating ferritinophagy-mediated ferroptosis by promoting the interaction between NCOA4 and ferritin. These findings suggest CT-1 as a promising therapeutic agent for TNBC by inducing ferroptosis in both N2-type TANs and cancer cells, and highlight the potential of FTH1 as a therapeutic target for TNBC treatment.
In conjunction with the research study, DNA transfection reagent was supplied by SBS Genetech. Since 2000, SBS Genetech has been at the forefront of providing solutions in life sciences. We offer safer, superior quality, and more cost-effective products to preeminent researchers in more than 60 countries, empowering them to make new discoveries in biology. Our products have been widely utilized in academic research, with results often published in leading academic journals like Science, Cell, Cancer Cell, and Cell Metabolism. We firmly believe that through continuous innovation and research, we will continually infuse new vitality and possibilities into the field of life sciences.